Literature DB >> 26287341

[Effects of hemoperfusion treatment on serum IL-23 and IL-17 levels in children with Henoch-Schönlein purpure].

Li Liu1, Yan-Ping Huang, Xia-Ling Fang, Yuan-Yuan Zhang, Ning Chen, Hong-Hong Hou.   

Abstract

OBJECTIVE: To study the effects of hemoperfusion treatment on serum interleukin-17 (IL-17) and IL-23 levels in children with Henoch-Schönlein purpura (HSP).
METHODS: Eighty-seven children who were diagnosed with HSP and who had received hemoperfusion treatment between January 2011 and December 2012 were enrolled. Twenty-seven sex- and age-matched healthy children were recruited as normal controls. Enzyme-linked immunosorbent assay (ELISA) was used to measure serum concentrations of IL-17 and IL-23.
RESULTS: The serum IL-23 and IL-17 levels in the HSP group were significantly higher than in the control group (P<0.05). After hemoperfusion treatment, the serum IL-23 and IL-17 levels in the HSP group were significantly reduced to the levels of the control group. Serum serum IL-17 level was positively correlated with serum IL-23 level (P<0.05) in children with HSP.
CONCLUSIONS: Hemoperfusion treatment can reduce serum IL-23 and IL-17 levels in children with HSP, suggesting that the treatment may be effective for HSP.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26287341

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  2 in total

1.  [Clinical effect and mechanism of hemoperfusion in treatment of children with severe abdominal Henoch-Schönlein purpura].

Authors:  Ying Zhu; Yang Dong; Da-Liang Xu; Jia-Yun Jiang; Lin Wu; Rui-Juan Ke; Shao-Han Fang; Yin Peng
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05

2.  Changes of inflammatory mediators and oxidative stress indicators in children with Henoch-Schönlein purpura and clinical effects of hemoperfusion in the treatment of severe Henoch-Schönlein purpura with gastrointestinal involvement in children.

Authors:  Ying Zhu; Yang Dong; Lin Wu; Fang Deng
Journal:  BMC Pediatr       Date:  2019-11-04       Impact factor: 2.125

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.